Nucleus Biologics has launched NB-Lux AI, a digital ecosystem designed to streamline media and buffer manufacturing workflows for advanced therapies. The platform integrates formulation, manufacturing and regulatory documentation into a single AI-enabled system aimed at accelerating development timelines.
AI-enabled ecosystem connects formulation to GMP manufacturing
Nucleus Biologics said the NB-Lux AI platform expands on its existing NB-Lux cloud-based ordering system by introducing AI-driven workflow automation and integrated manufacturing management.
The company stated that the platform links formulation design, feasibility analysis, quoting, approvals, manufacturing and documentation into one continuous digital process. According to Nucleus Biologics, this approach is intended to reduce manual processes and improve operational visibility.
New digital tools for media and buffer management
NB-Lux AI includes features such as formulation uploads, automated quoting, specification generation, purchase order integration and real-time order tracking. In addition, the system incorporates a secure digital repository for certificates of analysis, formulations and regulatory documentation.
The platform also supports automated bill of materials generation, inventory management and digital batch record initiation. Importantly, the company said the system is designed to support scale-up from research workflows to Excipient GMP manufacturing.
Focus on accelerating advanced therapy development
Nucleus Biologics stated that the system is designed to shorten manufacturing timelines for custom media and buffer solutions. The company said NB-Lux AI can support GMP turnaround times of between four and six weeks.
Furthermore, the platform integrates with Krakatoa manufacturing systems to support production continuity and process standardisation.
Digitalisation expands across bioprocessing workflows
The launch reflects broader industry efforts to digitise bioprocessing and cell therapy manufacturing workflows. AI-enabled systems are increasingly being used to reduce operational complexity, improve traceability and support regulatory compliance.
As advanced therapies continue to expand, demand is growing for integrated digital platforms capable of supporting scalable manufacturing and documentation requirements.
Explore more in Biotechnology.
